Johnson and Johnson subsidiary to team up with University of Queensland spin-out to treat rheumatoid arthritis.
Dendright Pty, a biotech spin-out from the University of Queensland (UQ), has announced a collaboration with Johnson and Johnson subsidiary Janssen Biotech to tackle rheumatoid arthritis. As part of the deal, the two will work together to move a new treatment, based on research from UQ’s Diamantina Institute, for the condition towards Phase I clinical…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
